Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30753364.
- Also identified by DOI 10.1093/cid/ciz122.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite glucose-6-phosphate dehydrogenase (G6PD) deficiency prevalence of 5% in the Amazon, primaquine is administered without G6PD screening. This is an important cause of hospitalization among Plasmodium vivax-infected individuals, leading to life-threatening anemia and acute renal failure across endemic areas. In Manaus, the frequency of primaquine-induced hemolysis was 85.2 cases per 100 000 primaquine users.
Medical subject headings
- Antimalarials
- Glucosephosphate Dehydrogenase Deficiency
- Malaria, Vivax
- Plasmodium vivax
- Primaquine
- Renal Insufficiency